Denosumab Therapy for Postmenopausal Women on Aromatase Inhibitors

Baseline Assessment

Measure bone mineral density (BMD) at the start of aromatase‑inhibitor (AI) therapy to identify patients at risk for fracture. 1
Initiate anti‑resorptive treatment immediately when the lumbar spine T‑score is ≤ ‑2.0 or when major risk factors (e.g., prior fracture, strong family history) are present. 1
If the T‑score is > ‑2.0, advise lifestyle measures (adequate calcium/vitamin D, weight‑bearing exercise) and repeat BMD after 1–2 years; accelerated bone loss should trigger anti‑resorptive therapy. 1

Denosumab 60 mg subcutaneously every 6 months is the preferred anti‑resorptive for AI‑treated women because it provides the strongest fracture‑reduction evidence in this population. 1
Alternative options include zoledronic acid 4 mg IV twice yearly or oral bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly, ibandronate 150 mg monthly). 1

Correct any hypocalcemia and vitamin D deficiency before the first denosumab injection. 2
Ensure daily calcium intake of ~1,000 mg and vitamin D supplementation of 800–1,000 IU. 1
Perform a comprehensive dental examination and complete any needed invasive dental procedures prior to initiating denosumab. 4

Administer denosumab precisely every 6 months; delays beyond 1 month increase the risk of rebound bone turnover and vertebral fractures. 3
In patients with chronic kidney disease (eGFR < 30 mL/min), check serum calcium within 14 days after each injection. 2
Maintain rigorous oral hygiene throughout treatment to minimise the risk of osteonecrosis of the jaw. 4

Discontinuation – Denosumab must never be stopped without transitioning to another anti‑resorptive agent (bisphosphonate, hormone therapy, or SERM) to avoid rebound bone loss. 5
Stopping denosumab leads to a rapid rise in bone‑turnover markers within 3–6 months, BMD loss back to pretreatment levels within 24 months, and a vertebral‑fracture risk that can approach 20 %. 7
Delayed dosing of 3–6 months raises the fracture hazard ratio to roughly 1.9. 3
At the osteoporosis dose, the incidence of osteonecrosis of the jaw is low (≈ 0–1 % per year), comparable with oral bisphosphonates. 4

Denosumab is contraindicated in organ‑transplant recipients receiving multiple immunosuppressive agents because safety data on infection risk are insufficient. 8

Initiating denosumab without a concrete plan to ensure uninterrupted 6‑month dosing is a critical error; poor adherence makes the drug unsuitable. 3
Failing to correct calcium and vitamin D status before the first injection can precipitate symptomatic hypocalcemia. 2
Allowing treatment gaps or “drug holidays” (as sometimes done with bisphosphonates) creates dangerous rebound bone loss unique to denosumab. 5